Meiji Seika Pharma and Hiroshima’s TwoCells Co. team up on osteoarthritis cell medicine
In a project limited to one year, the two companies will attempt to use bone marrow-derived mesenchymal cells (gMSC1) – a technology established by TwoCells – for the treatment of osteoarthritis. Meiji Seika Pharma is a producer of purified sodium hyaluronate for injections. TwoCells Co. news release, June 26, 2018